Abcam, ab221793, Anti-Choline Acetyltransferase antibody [EPR16590] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Choline Acetyltransferase antibody. Carrier free. Suitable for WB, IHC-P and reacts with Mouse, Rat, Guinea pig, Rabbit samples. Cited in 3 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR16590,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Rabbit, Guinea pig,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab221793 is the carrier-free version of
ab178850
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Choline Acetyltransferase (ChAT) also known as EC 2.3.1.6 acts as the enzyme responsible for synthesizing the neurotransmitter acetylcholine. It catalyzes the transfer of an acetyl group from acetyl-CoA to choline to form acetylcholine. ChAT is a protein with an approximate mass of 70 kDa and is expressed in cholinergic neurons throughout the central and peripheral nervous systems. High expression is observed in regions such as the basal forebrain and neuromuscular junctions which are important for cholinergic signaling.
Biological function summary
The enzyme plays an important role in cholinergic conduction by producing acetylcholine which functions in synaptic transmission. It does not function as part of a larger complex but its activity directly influences cholinergic synapses. Choline acetyltransferase function ensures the synthesis and availability of acetylcholine for release into the synaptic cleft initiating muscle contraction and modulating activity in the central nervous system.
Pathways
Choline acetyltransferase is critical in pathways governing neurotransmitter release such as the cholinergic synapse pathway. It interacts functionally with other proteins within this pathway including acetylcholinesterase which breaks down acetylcholine in the synaptic cleft. This interaction ensures proper neurotransmitter regulation and recycling maintaining synapse function and communication within neuronal circuits.
Alterations in choline acetyltransferase activity relate to neurological disorders including Alzheimer's disease and myasthenia gravis. In Alzheimer's disease reduced choline acetyltransferase function leads to decreased acetylcholine synthesis contributing to the cognitive decline observed in patients. In myasthenia gravis acetylcholine receptors are impaired but effective choline acetyltransferase activity is still necessary to manage neurotransmitter levels. A potential therapeutic angle involves targeting related proteins that exacerbate these conditions to support acetylcholine levels.